Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Petros Pharmaceuticals ( (PTPI) ).
On May 20, 2025, Petros Pharmaceuticals received a delisting notice from the Nasdaq Hearings Panel due to non-compliance with several Nasdaq listing rules, including minimum stockholders’ equity and bid price requirements. Consequently, the company’s stock will be suspended from Nasdaq trading on May 22, 2025, and is expected to trade on the OTC Markets under the symbol ‘PTPI’. The company plans to appeal the delisting decision, although there is no guarantee of a favorable outcome.
The most recent analyst rating on (PTPI) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Petros Pharmaceuticals stock, see the PTPI Stock Forecast page.
More about Petros Pharmaceuticals
Petros Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of therapeutics for men’s health issues.
Average Trading Volume: 7,791,091
Technical Sentiment Signal: Sell
Current Market Cap: $4.12M
For a thorough assessment of PTPI stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue